Does Insurance Cover Ketamine Treatment in Indiana?
Spravato is generally covered by Indiana Health Coverage Programs and by most commercial plans in Indiana, but almost always needs prior approval first. IV ketamine is off-label and is almost never covered by anyone. What you pay depends far more on your coverage than on which clinic you pick.
Who pays for what in Indiana
| If you have… | Spravato typically covered? | IV ketamine? | Prior approval likely? | What your prescriber must document |
|---|---|---|---|---|
| Indiana Health Coverage Programs | Usually, with prior approval | No | Almost always | Which antidepressants you have tried, for how long, and at what dose |
| Commercial (employer or marketplace) | Usually, with prior approval | No | Yes | A diagnosis, a baseline depression score, and failed antidepressant trials |
| Medicare (Part B) | Generally, as a clinic-administered medicine | No | Varies | Your prescriber can tell you what their billing requires |
| Medicare Advantage | Plan by plan — we cannot tell you | No | Usually | Ask your plan directly; network rules matter as much as criteria |
| VA or TRICARE | Through a referral pathway | No | Referral required | Ask your VA team; service-connected conditions typically carry no copay |
| Uninsured (paying cash) | You pay the clinic directly | You pay the clinic directly | Not applicable | Ask about self-pay rates and manufacturer patient assistance |
Indiana Medicaid covers esketamine under published state criteria, set out in bulletin BT202611 and effective for treatment dates from 1 October 2025. Spravato sits in the non-preferred column of the statewide preferred drug list, which means prior approval is required before your plan will pay. as of 22 Jan 2026 · Indiana Family and Social Services Administration (source 3, opens in a new tab)
For a first approval Indiana Medicaid requires all of the following: treatment-resistant depression, or major depressive disorder with suicidality plus a companion oral antidepressant; that you are 18 or over; that the prescriber is a psychiatrist or is consulting one; that you are enrolled in the Spravato REMS programme; and prescriber attestations about specific blood vessel conditions and about counselling on sedation risk if you also take benzodiazepines. A first approval runs up to six months for treatment-resistant depression, or two months for the suicidality indication. as of 22 Jan 2026 · Indiana Family and Social Services Administration (source 2, opens in a new tab)Note the asymmetry: Indiana requires a companion oral antidepressant only for the suicidality indication, not for treatment-resistant depression — which matches the FDA's monotherapy approval.
Commercial insurers in Indiana cover Spravato only with prior approval. Anthem Blue Cross and Blue Shield, the state's largest, requires inadequate response to two antidepressants at the highest tolerated dose. Ambetter lists it as a specialty tier medicine requiring prior approval. as of 1 May 2026 · UnitedHealthcare, Anthem and Ambetter (source 1, opens in a new tab)Anthem's published criteria date from December 2023, before the FDA's monotherapy approval, and still require a companion oral antidepressant — ask whether they have been updated. CareSource and Managed Health Services are Medicaid plans, so the state criteria above govern them rather than a plan policy.
UnitedHealthcare applies one national policy rather than a separate rule per state. It covers Spravato with prior approval for treatment-resistant depression, and requires a diagnosis made by a mental health professional, a baseline score on a recognised depression scale, failure of at least two antidepressants taken for at least eight weeks each at the highest tolerated dose, and a provider or setting certified under the Spravato REMS programme. as of 1 May 2026 · UnitedHealthcare (source 7, opens in a new tab)This is a national policy, so it reads the same wherever you live — which is why it is recorded once here rather than repeated in each state. UnitedHealthcare runs parallel medical and pharmacy versions; which one applies depends on how your clinic bills, and prior approval is needed either way.
UnitedHealthcare's national policy states that ketamine injection is investigational, and therefore not proven or medically necessary, for psychiatric conditions including depression, bipolar disorder and post-traumatic stress disorder. This is the clearest published statement of why commercial insurance rarely pays for IV ketamine. as of 1 May 2026 · UnitedHealthcare (source 7, opens in a new tab)This describes one commercial insurer. It does not describe any state Medicaid programme, none of which publishes criteria for racemic ketamine either way.
Under Original Medicare Part B in 2026 you pay a $283 yearly deductible first, and after that you generally pay 20% of the Medicare-approved amount for covered services. as of 1 Jan 2026 · Centers for Medicare and Medicaid Services (source 4, opens in a new tab)Deductible and premium amounts are set annually and change each January.
Indiana Health Coverage Programs in detail
Indiana Medicaid covers esketamine under published state criteria, set out in bulletin BT202611 and effective for treatment dates from 1 October 2025. Spravato sits in the non-preferred column of the statewide preferred drug list, which means prior approval is required before your plan will pay. as of 22 Jan 2026 · Indiana Family and Social Services Administration (source 1, opens in a new tab)
Indiana Health Coverage Programs drug list and coverage information
What has to be documented before it is approved
For a first approval Indiana Medicaid requires all of the following: treatment-resistant depression, or major depressive disorder with suicidality plus a companion oral antidepressant; that you are 18 or over; that the prescriber is a psychiatrist or is consulting one; that you are enrolled in the Spravato REMS programme; and prescriber attestations about specific blood vessel conditions and about counselling on sedation risk if you also take benzodiazepines. A first approval runs up to six months for treatment-resistant depression, or two months for the suicidality indication. as of 22 Jan 2026 · Indiana Family and Social Services Administration (source 1, opens in a new tab)Note the asymmetry: Indiana requires a companion oral antidepressant only for the suicidality indication, not for treatment-resistant depression — which matches the FDA's monotherapy approval.
In practice this documentation is what decides the outcome. If you have tried antidepressants that did not work, it is worth asking your prescriber to record which ones, at what dose, and for how long — before the request is submitted rather than after it is refused.
Commercial plans in Indiana
Commercial insurers in Indiana cover Spravato only with prior approval. Anthem Blue Cross and Blue Shield, the state's largest, requires inadequate response to two antidepressants at the highest tolerated dose. Ambetter lists it as a specialty tier medicine requiring prior approval. as of 1 May 2026 · UnitedHealthcare, Anthem and Ambetter (source 1, opens in a new tab)Anthem's published criteria date from December 2023, before the FDA's monotherapy approval, and still require a companion oral antidepressant — ask whether they have been updated. CareSource and Managed Health Services are Medicaid plans, so the state criteria above govern them rather than a plan policy.
UnitedHealthcare applies one national policy rather than a separate rule per state. It covers Spravato with prior approval for treatment-resistant depression, and requires a diagnosis made by a mental health professional, a baseline score on a recognised depression scale, failure of at least two antidepressants taken for at least eight weeks each at the highest tolerated dose, and a provider or setting certified under the Spravato REMS programme. as of 1 May 2026 · UnitedHealthcare (source 4, opens in a new tab)This is a national policy, so it reads the same wherever you live — which is why it is recorded once here rather than repeated in each state. UnitedHealthcare runs parallel medical and pharmacy versions; which one applies depends on how your clinic bills, and prior approval is needed either way.
The major insurers operating in Indiana are Anthem Blue Cross and Blue Shield, UnitedHealthcare, Ambetter, CareSource. Criteria change, and a policy published two years ago may no longer be what your insurer applies — ask for their current criteria in writing.
The manufacturer savings programme
Through the Spravato withMe savings programme, eligible patients with commercial insurance may pay as little as $10 per treatment for the medicine itself, subject to yearly maximum benefits and quantity limits. as of 18 Jul 2026 · Johnson & Johnson (source 5, opens in a new tab)The programme covers the medicine, not the office visit or the two-hour observation, which is often the larger share of the bill. The official terms state that a yearly maximum applies but do not publish the amount, so we do not either. Terms are set per calendar year.
The Spravato withMe savings programme is not available to anyone using a state or federal government health programme, including Medicare, Medicaid, TRICARE, the Department of Defense, and the Veterans Administration. as of 18 Jul 2026 · Johnson & Johnson (source 5, opens in a new tab)
That exclusion is not a decision your plan made and not something an appeal can change. If you are on Indiana Health Coverage Programs, Medicare, TRICARE or VA benefits, the copay card is not available to you, and any clinic suggesting otherwise has it wrong.
Medicare
Under Original Medicare Part B in 2026 you pay a $283 yearly deductible first, and after that you generally pay 20% of the Medicare-approved amount for covered services. as of 1 Jan 2026 · Centers for Medicare and Medicaid Services (source 4, opens in a new tab)Deductible and premium amounts are set annually and change each January.
If you have a Medigap policy it may cover most or all of that 20% share. Medicare Advantage works differently again: your plan sets its own copays and network rules, and we cannot usefully estimate those — your plan's member services line can.
What the FDA label and typical payer criteria say
Insurers generally look for a diagnosis of treatment-resistant depression, meaning depression that has not responded adequately to at least two antidepressants taken at a proper dose for a proper length of time. Most also want a baseline score on a recognised depression scale, and involvement from a psychiatrist.
On 17 January 2025 the FDA approved Spravato for treatment-resistant depression in adults either on its own or together with an oral antidepressant, so a companion oral antidepressant is now optional for this use — though it is still permitted. as of 17 Jan 2025 · U.S. Food and Drug Administration (source 5, opens in a new tab)This applies to the treatment-resistant depression indication only. The separate indication for major depressive disorder with acute suicidal ideation still requires an oral antidepressant — see spravato.approval_mdd_si. Widely-cited secondary sources give 21 January 2025; that is the manufacturer's announcement date, not the FDA action date on the approval letter.
On 31 July 2020 the FDA separately approved Spravato, used together with an oral antidepressant, for depressive symptoms in adults who have major depressive disorder with acute suicidal thoughts or behaviour; for this use the oral antidepressant is still required, and it is not a substitute for hospital care when hospital care is needed. as of 31 Jul 2020 · U.S. Food and Drug Administration (source 5, opens in a new tab)
None of this tells you whether you personally qualify. That is a judgement for a clinician who knows your history, working with your insurer. What it does tell you is what the conversation will be about, and what to bring to it.
If you are turned down
A refusal is not the end of the process. In order, the things that actually change outcomes:
- Ask for the specific reason in writing. "Not medically necessary" is not a reason; the criterion you failed to meet is.
- Ask your prescriber for a peer-to-peer review. This is a direct conversation between your prescriber and a clinician at the insurer, and it resolves a meaningful share of refusals — usually because the original request was missing documentation rather than because you did not qualify.
- Fill the documentation gap. Most refusals turn on trial length, dose, or a missing baseline score. Those are fixable.
- Request an external review. If the internal appeal fails, you can ask for an independent review outside the insurer. Your state insurance regulator can tell you how, and the deadline for asking is usually short — check it the day you receive the refusal.
If you have no insurance
Ask clinics directly whether they have a self-pay rate — it is often lower than the price they bill insurers. Ask the manufacturer about patient assistance, which is separate from the copay card and does reach some uninsured patients. And use our question checklist so the number you are quoted is a complete one rather than a starting point.